Comprehensive Atrophy Analysis with NeuroQuant Reports

October 14, 2024

Product: NeuroQuant
Disease: Alzheimer's disease, Epilepsy, Mild cognitive impairment, Neurodementias, Traumatic brain injury

Explore the clinical value of NeuroQuant in this detailed demonstration. We break down the Dementia, Seizure, and Total Brain Atrophy reports, showing how NeuroQuant enhances clinical analysis of neurological atrophy across various conditions.

Fill out the form to watch now:

Want to see more?

10/13/2026

NeuroQuant PET Is Now FDA Cleared

NeuroQuant PET is now FDA cleared, with centiloid estimation for amyloid PET and support for all FDA-approved dementia tracers.

10/13/2026

Know Where Your Patient Started: Centiloids in the Era of Anti-Amyloid Therapy

Neuroradiologist Dr. Suzie Bash explains why baseline centiloid values from amyloid PET are key to anti-amyloid maintenance dosing decisions.

10/01/2026

Comprehensive Insights on Metastatic Melanoma with NeuroQuant® CT | Dr. Niky Farid

By bringing key imaging findings together into a single structured report, NeuroQuant CT helps radiologists and clinicians quickly review critical information.

10/01/2026

Transforming Prostate Cancer Care with OnQ™ Prostate

OnQ Prostate adds color-coded imaging insights that help clinicians more clearly visualize regions.

10/01/2026

Why OnQ Prostate Is Different from Other Prostate Imaging Technologies

Learn how OnQ Prostate differs from other prostate imaging technologies and how its advanced diffusion modeling can provide clearer visualization.

10/01/2026

Why Urologists Choose OnQ™ Prostate for Better Lesion Detection

OnQ Prostate is helping clinicians gain deeper insights from prostate MRI using advanced diffusion modeling.

Our solutions

Our solutions

About

Support

Resources